Yes and these are US$ values not A$.
On top of this there is quite a wide variation within the precision oncology sub-category as some targets are broad and/or to major cancers like lung or breast, while other are for ultra-orphan indications. There is a big difference in EV depending on what tumour type the company is chasing - 85% of the EV is from less than 15% of cancer types - the top 5 cancer types by EV are lung, breast, melanoma, multiple myeloma, and lymphoma.
With all of these cancers there is good evidence that FTO is an important driver of carcinogenesis.
Ann: Change in substantial holding, page-58
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |